For instance, a finding using CRISPR-based engineering with higher fidelity discovered that KRAS (G12C) mutants primarily react to covalent-specific G12C inhibitors once EGFR is suppressed, whereas KRAS (G12D) mutants remain susceptible to EGFR inhibition in pancreatic human cancer model [96]. This evidence concerns the gene KRAS and pancreatitis.